Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Kyoto, Japan.
Clin Exp Hypertens. 2012;34(2):153-9. doi: 10.3109/10641963.2011.577493. Epub 2011 Oct 18.
The ancillary analysis of the KYOTO HEART Study (n = 3031) was designed to assess the combined treatment with calcium channel blocker (CCB) plus valsartan for high-risk hypertension. With-CCB (n = 1807) showed less primary events than without-CCB (n = 1224) (P = .037), in which acute myocardial infarction was significantly reduced. With-CCB plus valsartan (n = 773) showed lower incidence than with-CCB plus non-angiotensin receptor blocker (ARB) (n = 1034) (P = .0002), in which angina pectoris and heart failure were significantly reduced. Without-CCB plus valsartan (n = 744) was superior to without-CCB plus non-ARB (n = 480) (P = .0013), in which stroke was reduced. CCB-based therapy was useful, and CCB plus valsartan combination provided a more efficient prevention for high-risk hypertensive patients.
KYOTO HEART 研究的辅助分析（n=3031）旨在评估钙通道阻滞剂（CCB）联合缬沙坦治疗高危高血压。CCB 组（n=1807）的主要事件少于无 CCB 组（n=1224）（P=0.037），其中急性心肌梗死显著减少。CCB 加缬沙坦组（n=773）的发生率低于 CCB 加非血管紧张素受体阻滞剂（ARB）组（n=1034）（P=0.0002），其中心绞痛和心力衰竭显著减少。无 CCB 加缬沙坦组（n=744）优于无 CCB 加非 ARB 组（n=480）（P=0.0013），其中中风减少。CCB 为基础的治疗是有用的，CCB 加缬沙坦联合治疗为高危高血压患者提供了更有效的预防。
